Biohaven

Biohaven Ltd. was established as a spin-off from Biohaven Pharmaceutical Holding Company Ltd.Biohaven Ltd. is a clinical-stage biopharmaceutical company that combines expertise in neuroscience, immunology, disease-related biology, advanced chemistry, and global clinical trials to advance new therapies for patients. Their experienced management team has a proven track record of securing new drug approvals for diseases such as migraine and schizophrenia. Their research programs, built on a deep understanding of disease-related biology and neuropharmacology, are advancing treatments for Spinocerebellar Ataxia (“SCA”), Amyotrophic Lateral Sclerosis (“ALS”), Spinal Muscular Atrophy (“SMA”), epilepsy, depression, Obsessive-Compulsive Disorder (OCD), and neuropathic pain. Their neuro-innovation portfolio includes a range of drug candidates that modulate various nervous system targets, including Kv7 ion channels (“Kv7”), glutamate receptors, myeloperoxidase (“MPO”), myostatin, and Transient Receptor Potential (“TRP”) channels.